Labcorp (LH)
(Delayed Data from NYSE)
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings
by Zacks Equity Research
With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.
Walgreens (WBA), Village MD Plan to Expand Into Arizona
by Zacks Equity Research
Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening eight new Village Medical at Walgreens primary care practices in the Tucson area.
LabCorp (LH) Stock Moves -0.42%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $270.87, moving -0.42% from the previous trading session.
Zimmer Biomet's (ZBH) Pandemic Recovery Slow, Margin Woes Stay
by Zacks Equity Research
The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.
Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from a robust payment accuracy business. However, intense competition remains a woe.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
DaVita's (DVA) New Buyout to Enhance Transplant Experience
by Zacks Equity Research
DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.
Here's Why You Should Hold SmileDirectClub (SDC) Stock for Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub (SDC), backed by its expansion in the teledentistry space and the long-term growth target.
Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Quest Diagnostics (DGX) Expands Extended Care With New Buyout
by Zacks Equity Research
This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.
Abbott's (ABT) Organic Base Sales Grow Amid COVID Case Surge
by Zacks Equity Research
Even though COVID-19 case rates are surging, Abbott (ABT) is registering growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Inari Medical (NARI) Posts Solid Preliminary Q4, FY2021 Revenues
by Zacks Equity Research
Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.
5 Lucrative PEG Stocks for Value Investors
by Urmimala Biswas
Here are five value stocks, ACI, LH, PSX, FDX and SWRAY, matching our criteria.
QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit
by Zacks Equity Research
QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.
IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test
by Zacks Equity Research
Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.
Intuitive Surgical (ISRG) Posts Robust Preliminary Q4 Results
by Zacks Equity Research
Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2021 results driven primarily by da Vinci procedure volume growth.
Medtronic's (MDT) DTM SCS Endurance Therapy Study Data Positive
by Zacks Equity Research
Medtronic's (MDT) DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life and offering meaningful device longevity for patients.
LabCorp (LH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, LabCorp (LH) closed at $276.08, marking a -0.62% move from the previous day.
Abbott (ABT) Gets FDA Nod for New Cardiac Mapping System
by Zacks Equity Research
Abbott's (ABT) EnSite X EP System with EnSite Omnipolar Technology offers a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise.
Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist
by Zacks Equity Research
Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.
Quest Diagnostics (DGX) Posts Preliminary Q4 & 2021 Results
by Zacks Equity Research
Quest Diagnostics (DGX) posts preliminary fourth-quarter and full-year results, reflecting an increase in COVID-19 testing services and a steady recovery in the company's base testing volumes.
Bear of the Day: Cardinal Health (CAH)
by David Bartosiak
Earnings are not as healthy as they could be.
Here's Why You Should Retain Thermo Fisher (TMO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) strong end-market growth and focus on international regions.